Receipt of Glucocorticoid Monotherapy Among Medicare Beneficiaries With Rheumatoid Arthritis
Authors:
Open Access
- 19 February 2014
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 66 (10) , 1447-1455
Abstract
Objective: Using disease‐modifying antirheumatic drugs (DMARDs) improves outcomes in rheumatoid arthritis (RA) and is a nationally endorsed quality measure. We investigated the prevalence and predictors of receiving glucocorticoids alone for the treatment of RA in a nationwide sample of Medicare beneficiaries.Methods: Among individuals ages ≥65 years with RA enrolled in the Part D prescription drug benefit in 2009, we compared those with ≥1 DMARD claim to those receiving glucocorticoid monotherapy, defined as no DMARD claim and an annual glucocorticoid supply of ≥180 days or an annual dose of ≥900 mg of prednisone or equivalent. We fit multivariable models to determine the sociodemographic and clinical factors associated with glucocorticoid monotherapy.Results: Of 8,125 beneficiaries treated for RA, 10.2% (n = 825) received glucocorticoids alone. Beneficiaries with low incomes were more likely to receive glucocorticoids alone (12.3%; 95% confidence interval [95% CI] 10.9–13.8% versus 9.4%; 95% CI 8.6–10.1%), as were those living in certain US regions. More physician office visits and hospitalizations were associated with glucocorticoid monotherapy. Individuals who had no contact with a rheumatologist were significantly more likely to receive glucocorticoids alone (17.5%; 95% CI 16.0–19.0% versus 8.5%; 95% CI 7.4–9.5% for those with no rheumatology visits versus 1–4 visits).Conclusion: Approximately 1 in 10 Medicare beneficiaries treated for RA received glucocorticoids without DMARDs in 2009. Compared to DMARD users, glucocorticoid users were older, had lower incomes, were more likely to live in certain US regions, and were less likely to have seen a rheumatologist, suggesting persistent gaps in quality of care despite expanded drug coverage under Part D.Keywords
Funding Information
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (K23AR060259)
This publication has 27 references indexed in Scilit:
- Treatment of rheumatoid arthritis in the Medicare Current Beneficiary SurveyArthritis Research & Therapy, 2013
- Identification of rheumatoid arthritis patients using an administrative database: A Veterans Affairs studyArthritis Care & Research, 2012
- 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care & Research, 2012
- Primary care physicians' perspectives towards managing rheumatoid arthritis: room for improvementArthritis Research & Therapy, 2011
- Use of disease‐modifying medications for rheumatoid arthritis by race and ethnicity in the National Ambulatory Medical Care SurveyArthritis Care & Research, 2011
- Validation of rheumatoid arthritis diagnoses in health care utilization dataArthritis Research & Therapy, 2011
- Receipt of Disease-Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis in Medicare Managed Care PlansJAMA, 2011
- Societal cost of rheumatoid arthritis patients in the USCurrent Medical Research and Opinion, 2009
- Treatment disparity related to race/ethnicity and education in rheumatoid arthritis patients: Comment on the article by Constantinescu et alArthritis Care & Research, 2009
- Treatment of older adult patients diagnosed with rheumatoid arthritis: Improved but not optimalArthritis Care & Research, 2007